Psychedelics Company Profiles

Click on a company name below to view key financials, press releases and interviews.

ATAI Life Sciences

Beckley Psytech

Better Plant Sciences (PLNT)

CaaMTech

Champignon Brands Inc. (SHRM)

COMPASS Pathways (CMPS)

Cybin Inc.

Eleusis

Entheon Biomedical

Field Trip (FTRP)

Havn Life (HAVN)

Hollister Biosciences (HOLL)

MagicMed Industries

MindMed (MMED)

Mydecine Innovations Group (MYCO)

Numinus (NUMI)

Revive Therapeutics Ltd. (RVV)

Pα+ Psychedelic Bulletin #201: Dispatches from Prague and London; Texas Becomes Leader in Ibogaine Research as Governor Signs $50M Match-Funding Bill; High-Dose LSD Shows Potential in Depression, But Findings Are FragileJune 13, 2025
EU Member States as Laboratories of Democracy? Conference Discusses Czechia’s Psychedelic Future at Prague Castle • At ‘the Davos of Mental Health’, Investors Eye Psychedelics’ Next Chapter • Psychedelic Alpha at Psychedelic Science 2025 • High-Dose LSD Shows Potential in Depression Trial, But Findings Are Fragile • and more…
May 2025 Psychedelic Patent Update: Gilgamesh Broadens Moat Around Lead Candidate Following Positive Phase 2a Readout; Lykos Publishes Further Continuation Applications; Reconnect Joins Crowded 5-MeO-DMT Patent LandscapeJune 12, 2025
Explore or interactive database of psychedelic patent activity in May 2025 via our Pα+ interface. We also cover a handful of related headlines: from Gilgamesh Pharmaceuticals’ IP around its lead candidate, GM-2505, through to new published applications from Reconnect Labs that claim compositions of 5-MeO-DMT.
Psychedelic Bulletin #200: Can Czechia Deliver on Psilocybin Access? A Closer Look at ‘atai Beckley’; Q1’25 Psychedelic Lobbying Update; Catching Up with the Class of Bulletin #100June 6, 2025
The Class of Bulletin #100: Where Are They Now? • Can Czechia Deliver on Psilocybin Access and Provide a Model for the Continent? • A Closer Look at atai’s Potential Acquisition of Beckley Psytech • Q1’25 Psychedelic Lobbying Update • Holy Trips and Hot Takes: Religious Leaders Study Finally Published • and much, much more…
The Backyard Psychedelic Renaissance: How Bottom-Up Change Is Delivering Psychedelic AccessJune 4, 2025
Policy analyst Kody Zalewski calls for a greater focus on local reforms as a key driving force behind future reforms over larger geographies, and foregrounds some of the voices who are joining him in that call. In making his case, Zalewski surveys a range of such efforts, and successes, in his home state of Washington, which has been a hotbed for psychedelics-related liberalisation in recent years.
Breaking: atai Moves to Acquire Beckley, If Phase 2b 5-MeO-DMT Data DeliversJune 2, 2025
Psychedelic drug developers atai Life Sciences and Beckley Psytech are set to merge in a transaction that would value Beckley at around $370M. The combined entity, which would be named atai Beckley, would have a leadership team and Board reflective of both companies. Psychedelic Alpha spoke with sources close to the companies to learn more about the proposed merger and financing.

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.